Applying Belantamab Mafodotin in Community Practice

The faculty consider how to apply belantamab mafodotin in community practice, where clinicians typically see fewer patients with myeloma and want clear guidance and quick decisions. They discuss the therapy options available to patients and how access and distance from an academic center may shape the choice. They note that antibody-drug conjugates are familiar from other cancers, such as solid tumors and lymphomas, and proceed to describe an approach of assessing response and eye side effects after the first doses and then delaying or spacing doses as needed if the patient is responding to treatment.